News
Current position:Product Center > Cell lines > Immune checkpoints > BTLA-HVEM > H_HVEM aAPC CHO-K1 Cell Line
H_HVEM aAPC CHO-K1 Cell Line
Product Info

Cat. No:GM-C25499

Product:H_HVEM aAPC CHO-K1 Cell Line


BTLA-HVEM信号通路1.png


Materials required

Cell Growth Medium:F12K+10% FBS+1% P.S+4 μg/mL Blasticidin+4 μg/mL Puromycin

Cell Freezing Medium:90% FBS+10% DMSO

Assay Buffer:RPMI 1640+1% FBS+1% P.S


Description

B and T lymphocyte attenuator (BTLA; CD272) is a member of the Ig superfamily and is part of the checkpoint receptor family that negatively regulates immune cell activation. BTLA is mainly expressed on B cells, T cells, and dendritic cells. The natural ligand for BTLA is tumor necrosis factor receptor superfamily member 14 (HVEM; TNFRSF14).


BTLA and HVEM primarily regulate the function of T cells and antigen-presenting cells (APCs) through dynamic expression on the cell surface. Binding of BTLA to its ligand not only inhibits T cell proliferation, downregulates the T cell activation marker CD25, but also suppresses the production of IFN-y, IL-2, IL-4, and IL-10, without inducing cell apoptosis. Interaction between HVEM and BTLA leads to downregulation of T cell activation and proliferation.


Genomeditech H_BTLA Reporter Cell Line is a luciferase reporter cell line constructed based on the BTLA-HVEM signaling pathway. When H_BTLA Reporter cells are co-cultured with H_HVEM aAPC CHO cells (Genomeditech/GM-C25499), HVEM binds to BTLA, recruits SHP1, inhibits the TCR signal, thereby suppressing the expression of luciferase. By adding Anti-BTLA antibody to block BTLA-HVEM binding, restoring the TCR signal, normal expression of luciferase takes place, and the luciferase gene reading value represents the activation effect of the signaling pathway. This can be used for the activity detection of targeted functional antibodies against HVEM or BTLA.


Data
Current Position:Product Center > Cell lines > Immune checkpoints > BTLA-HVEM > H_HVEM aAPC CHO-K1 Cell Line
classify
H_HVEM aAPC CHO-K1 Cell Line
Product Info

Cat. No:GM-C25499

Product:H_HVEM aAPC CHO-K1 Cell Line


BTLA-HVEM信号通路1.png


Materials required

Cell Growth Medium:F12K+10% FBS+1% P.S+4 μg/mL Blasticidin+4 μg/mL Puromycin

Cell Freezing Medium:90% FBS+10% DMSO

Assay Buffer:RPMI 1640+1% FBS+1% P.S


Description

B and T lymphocyte attenuator (BTLA; CD272) is a member of the Ig superfamily and is part of the checkpoint receptor family that negatively regulates immune cell activation. BTLA is mainly expressed on B cells, T cells, and dendritic cells. The natural ligand for BTLA is tumor necrosis factor receptor superfamily member 14 (HVEM; TNFRSF14).


BTLA and HVEM primarily regulate the function of T cells and antigen-presenting cells (APCs) through dynamic expression on the cell surface. Binding of BTLA to its ligand not only inhibits T cell proliferation, downregulates the T cell activation marker CD25, but also suppresses the production of IFN-y, IL-2, IL-4, and IL-10, without inducing cell apoptosis. Interaction between HVEM and BTLA leads to downregulation of T cell activation and proliferation.


Genomeditech H_BTLA Reporter Cell Line is a luciferase reporter cell line constructed based on the BTLA-HVEM signaling pathway. When H_BTLA Reporter cells are co-cultured with H_HVEM aAPC CHO cells (Genomeditech/GM-C25499), HVEM binds to BTLA, recruits SHP1, inhibits the TCR signal, thereby suppressing the expression of luciferase. By adding Anti-BTLA antibody to block BTLA-HVEM binding, restoring the TCR signal, normal expression of luciferase takes place, and the luciferase gene reading value represents the activation effect of the signaling pathway. This can be used for the activity detection of targeted functional antibodies against HVEM or BTLA.


Data
Tel: 400-627-9288
Message consultation
reset
submit
Service
WhatApp
Phone
Message
Message consultation
reset
submit